Piper Jaffray Cos. Analysts Give Regeneron Pharmaceuticals Inc (REGN) a $447.00 Price Target
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been given a $447.00 target price by investment analysts at Piper Jaffray Cos. in a research report issued on Thursday. The firm presently has a a “hold” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would suggest a potential upside of 19.69% from the stock’s current price.
Other equities analysts have also issued research reports about the company. Vetr raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.09 price objective for the company in a research report on Tuesday, August 2nd. Leerink Swann reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, July 11th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 30th. Citigroup Inc. reaffirmed a “buy” rating and issued a $470.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 23rd. Finally, Brean Capital reaffirmed a “buy” rating and issued a $489.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 5th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $480.09.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.281% during trading on Thursday, reaching $378.255. 383,894 shares of the company traded hands. The firm has a market capitalization of $39.58 billion, a price-to-earnings ratio of 59.010 and a beta of 1.31. Regeneron Pharmaceuticals has a 52 week low of $329.09 and a 52 week high of $592.59. The company’s 50-day moving average price is $399.99 and its 200 day moving average price is $392.12.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/piper-jaffray-cos-analysts-give-regeneron-pharmaceuticals-inc-regn-a-447-00-price-target.html
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.65 by $0.17. The business earned $1.21 billion during the quarter, compared to analyst estimates of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The company’s revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.89 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals will post $11.02 EPS for the current year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction on Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the sale, the director now owns 15,125 shares in the company, valued at approximately $6,428,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in REGN. IFP Advisors Inc raised its stake in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares during the last quarter. Advisory Services Network LLC raised its stake in Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 326 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $140,000. Brave Asset Management Inc bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $157,000. Finally, Bessemer Group Inc. raised its stake in Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 171 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.